R-CDE compared with CDE
. | CDE . | R-CDE . |
|---|---|---|
| Reference | Sparano et al 11 | Present report |
| No. patients | 55 | 74 |
| Median age, y | 40 | 38 |
| Median CD4 count/μL | 227 | 161 |
| Histology, % | ||
| Burkitt or Burkitt-like | 22 | 28 |
| DLBCL or variants | 78 | 72 |
| Age-adjusted IPI, % | ||
| Low or low intermediate | 42 | 43 |
| High or high intermediate | 58 | 57 |
| CR rate, % (95% CI) | 45 (30-58) | 70 (59-81) |
| 2-year FFS, % (95% CI) | 38 (25-51) | 59 (47-71) |
| 2-year OS, % (95% CI) | 45 (20-58) | 64 (52-76) |
. | CDE . | R-CDE . |
|---|---|---|
| Reference | Sparano et al 11 | Present report |
| No. patients | 55 | 74 |
| Median age, y | 40 | 38 |
| Median CD4 count/μL | 227 | 161 |
| Histology, % | ||
| Burkitt or Burkitt-like | 22 | 28 |
| DLBCL or variants | 78 | 72 |
| Age-adjusted IPI, % | ||
| Low or low intermediate | 42 | 43 |
| High or high intermediate | 58 | 57 |
| CR rate, % (95% CI) | 45 (30-58) | 70 (59-81) |
| 2-year FFS, % (95% CI) | 38 (25-51) | 59 (47-71) |
| 2-year OS, % (95% CI) | 45 (20-58) | 64 (52-76) |